Arovella Therapeutics ASX: ALA

19/12/2023

Arovella Therapeutics (ASX: ALA) is pleased to release a year-end message from our CEO Dr Michael Baker, discussing the highlights from the Company during 2023 and the roadmap and milestones targeted for the year ahead.

10/12/2023

CAR-iNKT CELL PLATFORM DATA PRESENTED AT ASH

Highlights include:

• Superior animal survival data from Arovella’s CAR-iNKT Platform with CD28 co-stimulatory domain;

• New data utilising a different CAR-iNKT model on Arovella’s platform supports the extended use of the CAR-iNKT cell platform against multiple tumour types;

• Data presented at the 65th American Society of Hematology (ASH) annual meeting.

More at Arovella.com

04/12/2023

The iNKT Cell Therapy Revolution

In this video, we are going to explain what cell therapy is, and in particular, invariant natural killer T (i-N-K-T) cell therapy — in combination with CARs (chimeric antigen receptors).

After watching this video, you will be able to explain the ‘cell therapy revolution’ and grasp its future potential in the fight against cancer.

Welcome to Arovella Therapeutics ASX: ALA - at the time of making this video, we are the only Australian biotech company developing an iNKT cell therapy platform. Our core focus is on developing therapies to treat cancers.

04/12/2023

Our December 2023 Newsletter is now available at
arovella.com/newsletters

• Letter from the Chair;

• Progress on ALA-101;

• Expanding into solid tumours;

• Introducing ALA-105;

• Cytokine technology enhances iNKT cell platform;

• New explanatory whiteboard video & Instagram
account: https://www.instagram.com/wearearovella/ and more...

10/11/2023

Our CEO Michael Baker presents at the 2023 TCN Emerging ASX Gems Investment Conference.

10/11/2023

5 pharma and biotech stocks on the move in October:

"4) Arovella Therapeutics Limited (ASX: ALA)
Arovella shares continued their positive momentum in October with the share price up 30.9% for the month. Arovella is the best performer of the coverage universe over the 12-months to 31 October 2023, with the share price up 196.7% ..."

More at:

It was a tough month for the Pharma & Biotech coverage universe with 73.2% of share prices for companies in the universe either flat or negative for the month of October. There were however a few shining lights. We highlight 5 stocks that experienced positive moves in October. 1) Dimerix...

10/11/2023

ASX NEWS:
AGM Chairman's Address and CEO & MD Presentation

Download at arovella.com/asx-announcements

02/11/2023

We are pleased to announce that our CEO and MD, Dr Michael Baker, will today present at the Capital Network’s Emerging ASX Gems conference.

Dr Baker will provide an overview of Arovella’s iNKT cell therapy platform and how the technology provides important advantages over existing T-cell therapies and has the potential to be applied to both blood cancers and solid tumours.

arovella.com/investor-presentations

30/10/2023

New Conference Presentation at Australia’s premier life science investment conference, AusBiotech Invest.

arovella.com/conference-presentations

14/10/2023

Arovella Therapeutics (ASX:AVA) has inked a global and exclusive license agreement with Sparx Group to develop a world-first iNKT cell therapy targeting a protein called Claudin 18.2 (CLDN18.2).

11/10/2023

We have signed a global, exclusive License Agreement with Sparx Group (Sparx) for the use of a novel monoclonal antibody (mAb) sequence targeting Claudin 18.2 (CLDN18.2) in cell therapies. The mAb, known as SPX-101, has completed all preclinical proof-of-concept, safety and specificity studies and toxicology studies required to commence a Phase 1 trial to
treat gastric cancers.

Learn more: www.arovella.com/asx-announcements